4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine has been researched along with ritanserin in 1 studies
| Studies (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Trials (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Recent Studies (post-2010) (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Studies (ritanserin) | Trials (ritanserin) | Recent Studies (post-2010) (ritanserin) |
|---|---|---|---|---|---|
| 42 | 0 | 9 | 735 | 75 | 71 |
| Protein | Taxonomy | 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine (IC50) | ritanserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0012 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.001 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.047 | |
| Diacylglycerol kinase alpha | Homo sapiens (human) | 9 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.047 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0025 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0025 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0012 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.047 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine and ritanserin
| Article | Year |
|---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |